1 – 21 of 21
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
(
- Contribution to journal › Article
- 2021
-
Mark
European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma
2021) In International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 31(12). p.1508-1529(
- Contribution to journal › Article
- 2020
-
Mark
The LACC Trial and Minimally Invasive Surgery in Cervical Cancer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively : multicentre cohort study
(
- Contribution to journal › Article
- 2019
-
Mark
Risk of complications in patients with conservatively managed ovarian tumours (IOTA5) : a 2-year interim analysis of a multicentre, prospective, cohort study
(
- Contribution to journal › Article
- 2016
-
Mark
Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomas
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis (IOTA) group.
(
- Contribution to journal › Article
-
Mark
Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-Expressing platinum-resistant ovarian Cancer (PENELOPE)
(
- Contribution to journal › Article
-
Mark
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
(
- Contribution to journal › Article
-
Mark
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
(
- Contribution to journal › Article
-
Mark
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus
(
- Contribution to journal › Article
- 2014
-
Mark
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
(
- Contribution to journal › Article
- 2013
-
Mark
Panitumumab and Pegylated Liposomal Doxorubicin in Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type: The PaLiDo Study, a Phase II Nonrandomized Multicenter Study.
(
- Contribution to journal › Article
-
Mark
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
(
- Contribution to journal › Article
- 2011
-
Mark
Performance of the American College of Obstetricians and Gynecologists' Ovarian Tumor Referral Guidelines With a Multivariate Index Assay.
(
- Contribution to journal › Article
-
Mark
A Novel Approach to Predict the Likelihood of Specific Ovarian Tumor Pathology Based on Serum CA-125: A Multicenter Observational Study.
2011) In Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20. p.2420-2428(
- Contribution to journal › Article
- 2010
-
Mark
Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group
(
- Contribution to journal › Article
- 2008
-
Mark
Using Bayesian neural networks with ARD input selection to detect malignant ovarian masses prior to surgery
2008) 28th Annual International Conference of the IEEE-Engineering-in-Medicine-and-Biology-Society 17(5-6). p.489-500(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Pitfalls of CA-125 levels in the preoperative work-up of ovarian masses - Reply
(
- Contribution to journal › Letter
- 2007
-
Mark
Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors
(
- Contribution to journal › Article
-
Mark
External validation of mathematical models to distinguish between benign and malignant adnexal tumors: A multicenter study by the International Ovarian Tumor Analysis group
(
- Contribution to journal › Article